Antibody-Drug Conjugates in Perioperative Treatment of Muscle-Invasive Bladder Cancer: Expert Perspectives
By
Siamak Daneshmand, MD, Matthew D. Galsky, MD
Summary
This article discusses the emerging role of antibody-drug conjugates (ADCs) in the perioperative treatment of muscle-invasive bladder cancer (MIBC). It features insights from two leading urologic oncology experts — Dr. Siamak Daneshmand and Dr. Matthew D. Galsky — and is presented as an educational collaboration between Medscape Oncology and Cancer Support Community. The piece aims to update clinicians on the latest guidelines for ADC-based combination therapies in the perioperative setting for MIBC.
Source
Twitter / XAntibody-Drug Conjugates in Perioperative Treatment of Muscle-Invasive Bladder Cancer: Expert Perspectivesmdsc.peKey quotes
· 1 pulledAre your treatment plans for MIBC current? Learn about the latest guidelines for perioperative antibody-drug conjugate (ADC)-based combinations.
You might also wanna read
SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial
Nectin4-targeted fluorescence imaging probe improves bladder cancer detection and surgical precision
This article presents the development of NECTIN4-ICG, a Nectin4-targeted fluorescence imaging probe for bladder cancer diagnosis and surgery
TROP2 targeting reveals therapy-driven cell state dynamics in colorectal cancer
TAR-200 Drug System Eliminates Bladder Cancer in 82% of Resistant Patients
A new drug-releasing system, TAR-200, has shown remarkable success in treating high-risk non-muscle-invasive bladder cancer, eliminating tum
news.keckmedicine.org·10mo ago
New Drug Shows Promise in Penetrating Pancreatic Cancer's 'Fibrotic Fortress'
Pancreatic cancer has an extremely low survival rate (97% mortality within 5 years for metastatic cases) due to late detection and the forma
sciencealert.com·25d ago
Combination therapy with RAS inhibitors shows promise for pancreatic cancer regression and resistance prevention
This research article presents a study on a targeted combination therapy for pancreatic ductal adenocarcinoma (PDAC), one of the deadliest c
pnas.org·24d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.